Merck's hepatitis C drug boceprevir gains FDA panel's support

04/27/2011 | Wall Street Journal, The

An FDA panel of outside experts unanimously endorsed the approval of Merck & Co.'s boceprevir, saying the drug candidate marks an advance in the treatment of hepatitis C. The panel affirmed clinical data showing the efficacy of boceprevir in combination with standard medicines ribavirin and pegylated interferon. Merck proposed to commercialize it as Victrelis.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR